Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L.
N Katakami, S Morita, H Yoshioka, T Seto, Y Urata… - 2014 - ascopubs.org
8041 Background: Second-line therapy for advanced LA pts after progression on platinum-
based regimens typically employs chemotherapy (CT) or EGFR-TKIs. Both G and E …
based regimens typically employs chemotherapy (CT) or EGFR-TKIs. Both G and E …
Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
J Ahn, S Kim, M Ahn, J Lee, J Uhm, J Sun… - Journal of Clinical …, 2010 - ascopubs.org
7551 Background: Gefitinib and erlotinib are potent inhibitors of the epidermal growth factor
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …
receptor tyrosine kinase (EGFR TK), with single agent antitumor activity. In this randomized …
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)
PJ Hesketh, K Chansky, AJ Wozniak, P Mack… - Journal of Clinical …, 2007 - ascopubs.org
7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …
compared with good PS pts. Single agent and combination chemotherapy have been used …
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non …
Z Markóczy, V Sárosi, I Kudaba, G Gálffy, ÜY Turay… - BMC cancer, 2018 - Springer
Background Erlotinib is approved for the first line treatment of epidermal growth factor
receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of …
receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of …
Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: a retrospective study
S Yu, Y Wang, J Li, X Hao, B Wang, Z Wang… - Thoracic …, 2013 - Wiley Online Library
Background: The optimal strategy was not established for patients who initially responded to
gefitinib although re‐administration of epidermal growth factor receptor (EGFR) tyrosine …
gefitinib although re‐administration of epidermal growth factor receptor (EGFR) tyrosine …
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
F Grossi, E Rijavec, MG Dal Bello, C Defferrari… - Cancer chemotherapy …, 2012 - Springer
Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …
option for patients with advanced non-small-cell lung cancer who experienced disease …
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Y Ikezawa, H Asahina, S Oizumi, M Watanabe… - Cancer chemotherapy …, 2017 - Springer
Purpose A high proportion of patients with wild-type EGFR non-small cell lung cancer
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.
8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
相关搜索
- randomized phase erlotinib e in patients
- lung adenocarcinoma erlotinib e in patients
- erlotinib in patients previous chemotherapy
- gefitinib or erlotinib overall survival
- lung cancer gefitinib or erlotinib
- meta analysis gefitinib or erlotinib
- randomized phase lung adenocarcinoma
- randomized phase previous chemotherapy
- gefitinib in patients failure of erlotinib
- lung adenocarcinoma line treatment
- lung adenocarcinoma open label
- lung cancer overall survival
- meta analysis overall survival
- lung cancer gefitinib in patients
- lung cancer failure of erlotinib
- lung cancer administration of gefitinib